Latest FDA Stories
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
Represents Major Step In Company's Strategy to Target Large Multi-Billion-Dollar Market Opportunities MENLO PARK, Calif., Dec.
The agency says that the tools can spread a hidden uterine cancer, and advises against its use in the majority of women undergoing fibroid removal via hysterectomy or myomectomy.
AIX-EN-PROVENCE, France, Dec.
Finalized rules will usher in new era for the $19 Billion Automated Retailing Market CORONA, Calif., Dec. 1, 2014 /PRNewswire/ -- AVT, Inc.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
Integrated System Streamlines Diabetes Management for Patients CHESTERBROOK, Pa., Dec.
IGI Now Has Nineteen Applications Pending at the FDA BUENA, N.J., Dec. 1, 2014 /PRNewswire/ -- IGI Laboratories, Inc.
TARRYTOWN, N.Y., Dec. 1, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.
Accurate Norovirus Detection in as Little as One Hour SUNNYVALE, Calif., Dec. 1, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S.
- A transitional zone between two communities containing the characteristic species of each.